The widely prescribed hepatitis C medication, Harvoni, offers a cure for 90 percent of patients who take it. Yet, insurers have instituted significant cost-containment measures to prevent patient access, including burdensome prior authorizations that include a waiting period of several months and blanket denials of care for patients who are “not sick enough” or for those who have substance use disorders. These policies block access to lifesaving treatment for hepatitis C patients. These discriminatory cost containment policies must be challenged. Read more here.
Last Updated on May 7, 2020 by Aimed Alliance
